Audio Journal of Oncology September 9, 2022 By Peter M Goodwin PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung c
Audio Journal of Oncology
September 9, 2022
By Peter M Goodwin
PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ESMO).
Charles Swanton FRCP BSc PhD, Professor and Senior Group Leader of the Francis Crick Institute, Consultant Oncologist at University College London Hospital specializing in Thoracic Oncology and ESMO Scientific Co-Chair, told the Audio Journal of Oncology that prevention was better than cure wherever possible, and that the oncogenic mechanisms his group’s research had uncovered held important keys to reducing the cancer burden globally.
Swanton’s group had investigated the relationship between air pollution and lung cancer in never smokers. “We’ve tried to establish how air pollution causes lung cancer,” he told OT. “Through a series of steps involving animal models and human analyses we’ve found that air pollution results in the release of a cytokine called: interleukin 1-beta from epithelial cells in the lung, that generates and transforms cells with pre-existing mutations—that occur normally due to aging—into tumor cells.”
He discussed his findings during the ESMO congress in Paris with the Audio Journal of Oncology’s Peter Goodwin.
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Jeanne Tie MD, ESMO Berlin: Liquid Biopsy Brings Chemo-free Option for Patients with Stage Three Colon Cancer
Some patients being treated for stage three colon cancer could avoid the use of chemotherapy and be spared toxicities such as neuropathy: according to a study in which ctDNA liquid biopsy monitoring f
Paul H Cottu MD PhD, ESMO Berlin: Chemo-Free Regimen with Neoadjuvant CDK 4/6 Inhibition plus Endocrine Therapy Benefits Patients with High-Risk ER+ HER2- Early Breast Cancer
Aan identifyable subset of patients with high-risk ER+ HER2- early breast cancer better off without chemotherapy